Taken together, our in vitro and in vivo results suggest that another potential mechanism by which STAT3 inhibition attenuates amyloid pathogenesis and its associated neurovascular deficits is by reducing Aβ-induced oxidative stress production and its pathologic impact on LRP-1 expression. Here, LRP1 is linked to amyloidosis.